The document discusses the evolution of intracavitary brachytherapy for carcinoma of the cervix over time. Key developments include changing radiation sources from radium to cesium-137 and cobalt-60, and the introduction of high-dose rate and pulsed-dose rate brachytherapy. Imaging technologies like ultrasound, CT, and MRI now allow for image-based treatment planning to better define tumor volumes and conform the radiation dose. Modern brachytherapy techniques have improved local control rates for cervical cancer and reduced toxicity compared to older methods.
Management of cacrinoma cervix: Techniques of radiotherapy (2D conventional, 3D Conformal radiotherapy (3DCRT) and IMRT with a review of various contouring guidelines.
Management of cacrinoma cervix: Techniques of radiotherapy (2D conventional, 3D Conformal radiotherapy (3DCRT) and IMRT with a review of various contouring guidelines.
It is an oncologic emergency. This slides contains a brief discussion on mechanism of spinal cord compression , common malignancies presenting with spinal cord compression , approach to a patient with cord compression like features and management this catastrophic situation.
This ppt explains about Electronic Brachytherapy which is a very special type of Brachytherapy in Radiation therapy. This presentation also demonstrates classifications of brachytherapy, Sources used for Brachytherapy, Advantages and disadvantages of electronic Brachytherapy, Different companies providing Electronic Brachytherapy machines and it portraits working method and components of Electronic Brachytherapy Machine.
Similar to Evolution of Intracavitary brachytherapy for carcinoma of cervix (20)
Techniques for Inguinal/Groin IrradiationAjeet Gandhi
Inguinal radiotherapy delivery is many a times a complex dosimetric uncertainty and we need to judiciously choose the technique for best patient outcome
Incorporating data for management of breast cancerAjeet Gandhi
The guidelines are mostly western and in many scenarios, it is difficult to apply them to Indian population. We need to take in to consideration many factors while applying the data
While the role of radiation therapy in carcinoma cervix management is undauntable for all stages. Recurrent carcinoma cervix need a lot of personalisation
Role of radiotherapy in recurrent carcinoma cervixAjeet Gandhi
While the role of radiation therapy in carcinoma cervix management is undauntable for all stages. Recurrent carcinoma cervix need a lot of personalisation
Controversies in the management of rectal cancersAjeet Gandhi
Management of rectal cancers have undergone a huge paradigm shift over the last decade. One the one hand, it has opened up new avenues; it also has thrown up new challenges and controversies
T4 Larynx cancer can be treated with ChemoradiotherapyAjeet Gandhi
Traditionally, T4 larynx cancers are recommended to undergo surgery as the primary modality of treatment. However, a select group of patients may be treated with CTRT
Advances in radiation oncology:Cancer careAjeet Gandhi
Radiation therapy has tremendous capacity for cancer cure. Advancement in last few decades have further enhanced its outcome. Global access would save many lives
A novel technique of radiation delivery with ultrahigh dose rate radiation therapy delivered in milisecond of time. Although, still in investigational phase
Management of Anemia in cancer patientsAjeet Gandhi
Anemia in cancer patients are important both in terms of quality of life as well as response to therapy. Cause of anemia is multi-factorial and its management is critical in optimizing best outcomes of cancer patients
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
VERIFICATION AND VALIDATION TOOLKIT Determining Performance Characteristics o...
Evolution of Intracavitary brachytherapy for carcinoma of cervix
1. Evolution of intracavitary brachytherapy in Carcinoma
Cervix
DR AJEET KUMAR GANDHI
MD (AIIMS), DNB, UICCF (MSKCC,USA)
ASSISTANT PROFESSOR, RADIATION
ONCOLOGY
DR RMLIMS, LUCKNOW
2. Overview of presentation
Role of brachytherapy in carcinoma cervix
History of Brachytherapy in carcinoma cervix
Evolution :
Radiation physics
Radiobiology
Treatment delivery techniques
Imaging
Current standard of ICBT practices
Clinical results and future research
Conclusion
3. Role of brachytherapy in carcinoma cervix
Integral component of radical treatment for all stages
Several methods: Intracavitary, Intravaginal, Interstitial or a combination of
these
Use of brachytherapy is associated with increased overall survival as well as
increased local control rates* (5 year survival 65% versus 50%)
Advantages:
Organ preservation, less normal tissue damage, less radiation morbidities
*Han K et al. IJROBP 2013;87:111-119
5. Margaret Abigail Cleaves (1848-1917)
September 16, 1903: Treated a case of carcinoma cervix initially
treated with Intracavitary X-rays: Radium vials applied to fornices 10
min Day 1 and 5 min Day 2 [Intracavitary radium for gynecological
malignancies Med Rec 1903;64:601-606]
Albert Doderlein (Germany; 1903) and William J Morton (New York;
1903): treated carcinoma cervix with radium
6. Early history: 1903-1913
1908, 1910, 1912: ICBT started in Vienna, Stockholm,
Paris
1912: Gosta Forssell (Stockholm) reported 24 cases
of carcinoma cervix treated with radium therapy
1913: Robert Abbe (New York) reported long term
control of carcinoma cervix-8 years
7. Early applicators: 1903-1913
Figure 1 : Wickham and Degrais; St. Louis hospital, Paris
Figure 2&3: Carl Josef Gauss (‘Inter-cervical tubes’ and Portio plates): Mostly used in
Germany
8. 1903-1913
Sporadic reports of ICBT from different parts of world
Most reports: “Enthusiastic or magical” reporting rather than
scientific
There was little knowledge of the biological effects of treatment on
the normal and tumor tissues
Uterine tandem was used alone without vaginal colpostats
Non-durable responses in these patients or overwhelming
toxicities
No definite consensus on dose prescription and reporting and
mostly were empirical and personal opinion based
9. Dawn of a new era: 1910-1930
Stockholm System: Gosta
Forssell (1910)
Paris System: Claude Regaud
(1912)
Manchester System : Todd and
Meredith (1930)
10. STOCKHOLM METHOD
Intra-vaginal boxes Silver or gold ; Intrauterine tube: flexible rubber
Applicator not fixed together
Unequal loading
30 - 90 mg (50 mg) of radium in uterus
60 - 80 mg in vagina
Three insertions each of 22 hours separated by 1-3 weeks
Total prescribed dose: 6500-7100 mg Ra
4500 mg Ra contributed by the vaginal box
Dose rate-110R/hr or 2500mg/hr/#
Limited use of EBRT.
11. PARIS METHOD
Single application of radium for 120 hours
Two cork colpostats (cylinder) with 13.33 mg radium in each and an
intrauterine tube of silk rubber containing 33.3 mg of radium
3 radioactive sources, with source strength ratio of 1:1:0.5 in
uterus
Delivers a dose of 5500 mg-hrs of radium over a period of five
days at dose rate of 45R/h
Equal loading of sources in uterus and vagina
Combined with EXTRT.
12. DRAWBACKS OF PARIS AND STOCKHOLM
SYSTEMS
Long treatment time, discomfort to the patient, no specific dose
prescription
Uterine sources arranged in a line from the external os to nearly the top
of the uterine cavity
Both systems preferred the longest possible intrauterine tube to
increase the dose to paracervical region and pelvic region lymph
nodes.
13. MANCHESTER
SYSTEM
Developed by Todd & Meredith in 1930 and pioneered by Patterson &
Parker
Unique dosage system necessary for pelvis
roentgen unit in favor of mg/hrs
Dose to a point
Constant dose rate
Reproducible technique
14. Point A & B
Classic definition : fixed point 2cm
lateral to the center of uterine canal and
2 cm above from the mucosa of the
lateral fornix
Revised definition #1: 2 cm above the
external cervical os and 2 cm lateral to
midline
Revised definition #2 (1953, Tod &
Meredith): 2 cm above the distal end of
the lowest source in the tandem and 2
cm lateral to the tandem
Common variation: use flange at cervical
os
15. Initially used radium units were 6.66mg but later
changed to 2.5 mg each.
Two application 72hrs apart with 4 days in between
Dose of 8000R was delivered at pt A when radium used
alone for stage I/II ds
When radium was used along with deep-X ray therapy
for stage III or IV ds radium dose to pt A reduced to 6500R.
16.
17. MANCHESTER SYSTEM : PRELOADED
APPLICATORS
AP & Lateral radiographs were taken to
verify appropriate applicator position
not for dosimetry
18. Manchester System
Advantages: Well studied, reproducible, better control rates and morbidity
Dis-advantages:
Loose system
Based on ideal cervical and para-cervical anatomy
Radiation hazard : being a preloaded system.
Need for fixed preloaded systems and afterloading systems!!!
19.
20. Pair of cylindrical “small” ovoids (2 cm in
diameter) with inter-locking handles.
Plastic jackets of two thicknesses are
added to made medium (‘2.5 cm in
diameter) and large (3 cm in diameter)
sizes.
Fletcher preloadable applicators
Fletcher et al. Radiology 60:77-84, 1953
21. •In 1960-Ulrich K Henschke first described Manual
afterloading
•In 1962-Walstram first described remote afterloading
•In 1964- First developed Remote afterloading device
22. Fletcher afterloading colpostats
a. Fletcher-Suit
rectangular-handle model
b. Round-handle,
lighter model.
In 1958, Suit et al. developed the first afterloadable Fletcher colpostat
In 1978, Delclos et al. improved design of the afterloadable Fletcher colpostats
Fletcher
Suit
Delclos
23. IDEAL APPLICATION
Tandem
1/3 of the way between S1 –S2 and the
symphysis pubis
Midway between the bladder and S1 -S2
Bisect the ovoids
Ovoids
Largest
Separated by 0.5-1.0 cm
Axis of the tandem-central
Bladder and rectum -should be packed
away from the implant
25. Radium: The pitfalls
•Heterogeneous beam & non uniform dose distribution
• Low specific activity : 1 Ci/gm
• High energy (0.047-2.45 MeV)
• Rn 222 being the gaseous daughter product - threat of leaks from long bent
needles
• Storage & disposal of leaked sources
26. CESIUM 137: ( Cs137)
T1/2 : 30 yrs
Relatively cheaper, extraction simple
No gaseous decay product, safer than
Ra
γ ray energy = 0.662 MeV
β filtration – 0.5 mm stainless steel
Available in tubes, needles, pellets
Replaced Ra in t/t of gynecologic
cancers
COBALT 60 (60Co)
T1/2 = 5.26 yrs
Each disintegration produces 2 y rays of
energy 1.33 & 1.17 MeV (avg energy 1.25
MeV)
High specific activity , miniaturized source
can be made and used in brachytherapy.
27. ICBT: 1960s-1980s
Cesium-137/Co-60 had almost replaced Radium at most centres
Low dose rate brachytherapy most commonly used
Manchester method became the standard of practice
Remote after loaders were rapidly phasing out all the manual after loaders
Tandem and Ovoid standard Fletcher-suit applicators were commonly
used
X-rays were used for verification but not for dosimetry
28. Ir-192 : A near ideal radioisotope
Compatible with after loading techniques
Ideal energy (0.3-0.4 MeV) – monoenergetic – more radiobiological effect
Flexible & malleable – can be used in form of wires of any size
Energy is low – thinner shields required for radiation safety
β-energy is low – so lesser filtration required
Product (Pt192) not radioactive
Easily available , less costly
x Limitation
Short half life (73.8 days) so source has to be replaced every 3 months
29. Intracavitary Brachytherapy :Changing
Dose Rates
1968 : HDR brachytherapy was introduced
with cathetrone containing Co-60 sources.
1982 : MDR brachytherapy was introduced
with Selectron MDR using Cs-137 pallet
sources.
33. PDR Brachytherapy
Series of short HDR
treatments ( 10 minute
pulse repeated at 1 hr
intervals)replacing the
Continuous LDR treatment
lasting several days.
Overall time remains same as LDR
Source strength : 1 Ci
ADVANTAGE:
•Radiobiologically nearer to LDR
•optimization possible
•Nursing care possible without radiation hazards
Nucletron
PDR
After loader
34. ICRU-38: Dose-Volume specification for reporting intracavitary
Therapy in Gynecology [1985]
• Definition of terms and concepts for ICBT
• Treatment techniques
• Absorbed dose pattern and volumes
• Specification of radioactive sources
• Recommendations for reporting absorbed doses and volumes in ICBT
• TRAK
• Reference volume
• Absorbed dose at reference points
• Calculation of dose distributions
• Time-Dose pattern
• Radiobiological considerations
• Recommendations for reporting time-dose pattern
37. Time to move from points to
profiles
Point A &B are not anatomical sites. The variation in position and distribution of
sources significantly changes the anatomic structures in which points A & B are
located.
No one point is representative even of a small volume.
It is viewed as a treatment reference point.
38. Image based brachytherapy
Newer imaging modalities are used to define target
volumes
USG, CT, MRI (preferred), PET
Prescribed dose - related to the target
Shape the spatial dose to conform to the target volume
Reduce dose to normal tissues & hence reduce the normal tissue
toxicity.
Escalate dose to the tumor to produce greater rates of local
control
39.
40. GTV
Includes macroscopic tumor extension - clinical examination & as visualized on MRI
At diagnosis GTVD
At brachytherapy GTVB
CTV
High risk CTV (HR CTV)
Major risk of recurrence because of residual macroscopic tumor
whole cervix + presumed extra-cervical tumour extension at time of BT
Intent is to deliver a total dose as high as possible to eradicate all residual
macroscopic tumor ( 80-90 Gy)
Intermediate risk CTV (IR CTV)
Major risk of recurrence in areas that initially had macroscopic extent of disease with
residual microscopic disease at time of BT
Intent is to deliver dose appropriate to cure microscopic disease in cervix cancer,
(60Gy)
41.
42. Dose prescription
The prescribed dose is always related to the target.
The prescription dose is the planned dose to cover this target as completely as
possible.
HR-CTV Dose
Small tumor – 80-85 Gy
Large tumor, good response – 85-90 Gy
Large tumor, poor response - 90+ Gy
IR-CTV ~ 60 Gy
For comparison, dose reporting should refer to the prescribed dose to the image-
based target & to the traditional system - point A
46. HDR Brachytherapy In Carcinoma Cervix –Summary Of
Retrospective Analysis
Author Stage Pt No. EBRT
(GY)
HDR GY*# LC Survival Late
Complic
ations
Lorvidhya et al I-III 1992 30-50 7-7.5 *4
5.5-6 *6
75.2% 68.2%(5y) 4.8%b
3.5%u
Potter et al I-IV 189 48-50 7 * 3-6 77.6%(3Y) 58.2%
Toita et al I-III 88 50 6*3 82%(3Y) 77% 6%r
4%b
2.9%u
Sood et al I-III 49 45+9 9-9.4*2 77%
88% cct
78% 4.1%
Patel et al I-III 121 40-46 9*5
9*2
87.5% 1.7%u
Ferringo et al I-III 118 40-50 6*4 65% 55% 6%r
6%b
1.7%u
Souhami et al I-IVA 282 45 8*3 75%(15y) 57% 6.3%b
3.5%u
47. HDR V/S LDR BT IN CA CX – RCTS
Pt. No. Local Control 5 YR Survival
Author Stage EBRT
(GY)
LDR HDR LDR% HDR% LDR% HDR%
Shigema
tsu et al
IIB-III 40 106 143 77 90 55 55
Teshima
etal
I
II
III
40 171 259 73 76 89
73
45
66
61
47
Patel et
al
I-III 35-45 246 236 80 76 58 58
Hareyam
a et al
II
III
50 71 61 87
60
69
51
Lertsang
ua et al
I-III 40-54 109 112 89 86 71 68
50. Xray Ct scan MRI 2D/3D
ABS (USA) 43% 56% 1% 77%/21%/3%
Canada 50% 45% 5% 50*%/44%
Australia
NZ
30% 65% 15% 65%/35%
Results of Survey for 3D Brachytherapy
51. Current standard of practice
Remote afterloaders (HDR) with Ir-192 most commonly used
LDR, PDR limited to some Institutions
Fletcher suit (tandem-ovoids) and Ring applicators (Vienna) in common
practice
X-ray based dosimetry still common followed by CT and MRI
Point-A based prescription mostly, less widespread use of ICRU-38;
GEC-ESTRO
53. 1984: LDR brachytherapy [Cesium-137; Remote after loading; X-ray
based treatment; NPS; Point A based prescription]
2003: HDR V2 (microselectron); PLATO TPS; PDR
2004: CT based planning (Use of bladder & rectal points)
2006: HDR V3 (microselectron); Oncentra TPS
2007: Inverse planning simulated annealing
2007-2008: Sedation instead of general anesthesia
2013: MRI based volumetric brachytherapy
54. Rath GK et al. Clin Oncol (R Coll Radiol).1994
Results of radical radiotherapy in carcinoma of
the uterine cervix stage I-III
• 271 patients
• Dose
• Early cases (34 Gy X2 f/b 36 Gy external radiotherapy )
• Late stage disease 50 Gy of external radiotherapy f/b 30 Gy to point A
• Late Grade III bladder and bowel complications were 2.5% and 4.7%
respectively.
• The actuarial 5-year survivals were 65%, 63% and 35% for Stages I, II and
III disease, respectively
55. 48 patients (2003-2005)
Follow-up period 3 to 50 months (median: 15 months)
Overall grades III to IV late toxicity rate at 50 months was 6%
The actuarial recurrence-free survival in stages I to II was
82% and stages III to IV was 78%
59. Re-emergence of 60Co as brachytherapy source
Modern techniques → Sources of higher Sp
Activity → Decreased source size compatible
with remote afterloading stepping source
machines for HDR.
No need for frequent replacements
Cost effective
Low operating cost.
64. IJROBP 2015; 92 (5): 1093-1100
111 patients (2003-2009); 57% stage III-IV and 26% stage II
Median follow up: 42 months
Late grade toxicities: 8%
4 year local, loco-regional, distant control: 94%, 91.9% and
69.1%
65.
66. Phase II Randomized Study of brachytherapy versus
chemobrachytherapy in locally advanced cervical
cancer
Eligibility
Stage IIB to IVA SCC of carcinoma
cervix in patients aged 20 – 65 years
Patients treated with radical EBRT 50.4
Gray / 28 # / 5.5 weeks with concurrent
weekly cisplatin ( 40 mg / m2 )
R
HDR INTRACAVITARY
RADIOTHERAPY 7 GRAY FOR THREE
WEEKLY SESSIONS
HDR INTRACAVITARY RADIOTHERAPY 7
GRAY FOR THREE SESSIONS WITH
CONCURRENT CHEMOTHERAPY
Computer
generated
randomization
1:1
ASSESSMENT OF
TOXICITY,
LOCOREGIONAL
CONTROL AT 1, 3 AND 6
MONTHS
67. Phase II Randomized Study of brachytherapy versus
chemobrachytherapy in locally advanced cervical
cancer
68.
69. Conclusion
ICBT in carcinoma cervix has evolved over the last century in many
spheres:
Remote after loading system, Radiation source
Dose rates, Applicator
Points to Volumes
X-rays to MRI/CT/PET
Overall it has made us more:
Safe, accurate, reproducible
Decreased morbidities
Improved outcomes
70. Conclusion
Future research should focus on:
More accessible and cost effective (USG & CT vs. MRI)
Precise definition of the tumor volume (MRI, PET-CT)
Adapt to the weekly changes in the treatment volume (adaptive
planning)
Improving local control further (integration of systemic therapy)
Optimum dose and dose per fraction (resource constrained setting!!)
Research in to a competitive or better source than Ir-192